Pyxis Oncology Inc (PYXS) Stock Price, Quote & News

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monothera...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 453 3596

Website: www.pyxisoncology.com

Address:

321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States

StockScanners Jul. 28 at 12:33 AM

$PYXS reached 2.99

0 · Reply

AC_TRADER Jul. 23 at 5:44 PM

$PYXS Chart made with @TrendSpider https://share.trendspider.com/chart/PYXS/7594xsw7hw

0 · Reply

dixiebull Jul. 23 at 1:06 PM

$ADVB $PYXS $NUVB $LABT $PN ADVB as usual the first one on my watchlist is the nicest

0 · Reply

dixiebull Jul. 23 at 11:18 AM

$ADVB $PYXS $NUVB $LABT $PN ADVB first on watchlist, as ususal

0 · Reply

AtariLynx Jul. 23 at 5:42 AM

$PYXS with no news it will back around 2.2 in the next days.

0 · Reply

InItToWinIt100 Jul. 23 at 5:37 AM

$PYXS Those $2.50 calls are looking good!

0 · Reply

hyenapete Jul. 23 at 5:13 AM

$PYXS

0 · Reply

StockScanners Jul. 23 at 2:31 AM

$PYXS keep watch if this holds above 2.45

0 · Reply

topstockalerts Jul. 22 at 10:21 PM

$PYXS there’s very little to dislike about this setup.

0 · Reply

dixiebull Jul. 22 at 8:52 PM

$ADVB see if 10 can hold now for another run to 13 and 15 $PYXS nice move to 2.56, if that 2.50 holds it can see 3 to 3.25 $NUVB bounced off 6 to 6.60, see if 6.35 holds for a move to 7 and 7.50 $LABT sitting at 3.50 so watch for volume for a move to 5 $PN nice break of 10 to 11.50, see if 8.50 holds now for a move to 10 and 12

1 · Reply

Pyxis Oncology announces up to $114M private placement

Jun 30, 2026, 7:30 AM EDT - 27 days ago

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Jun 4, 2026, 7:35 AM EDT - 7 weeks ago

Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 20, 2026, 3:30 PM EDT - 2 months ago

Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 2:35 PM EDT - 2 months ago

Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-14T13:11:04.000Z - 2 months ago

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

May 14, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

May 14, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Earnings release: Q1 2026

May 13, 2026, 7:30 AM EDT - 2 months ago

Pyxis Oncology to Participate in Upcoming Investor Conferences

May 13, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Slides: Investor presentation

May 7, 2026, 4:05 PM EDT - 2 months ago

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

2026-05-05T11:59:21.000Z - 2 months ago

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

2026-05-05T11:30:55.000Z - 2 months ago

Pyxis Oncology initiated with an Outperform at Wedbush

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Pyxis Oncology Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Pyxis Oncology Proxy statement: Proxy filing

Apr 17, 2026, 4:05 PM EDT - 3 months ago

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

2026-03-24T10:51:42.000Z - 4 months ago

Pyxis Oncology price target lowered to $8 from $9 at Stifel

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Pyxis Oncology Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Pyxis Oncology Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Pyxis Oncology Slides: Corporate presentation

2026-02-03T12:00:53.000Z - 6 months ago

Pyxis Oncology appoints board member Thomas Civik as Interim CEO

Feb 3, 2026, 6:45 AM EST - 6 months ago

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

2025-12-19T14:30:40.000Z - 7 months ago

Pyxis Oncology price target lowered to $5 from $8 at RBC Capital

2025-12-19T11:15:22.000Z - 7 months ago

Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright

Dec 18, 2025, 8:30 AM EST - 7 months ago

Pyxis Oncology Transcript: Study Update

Dec 18, 2025, 8:30 AM EST - 7 months ago

Pyxis Oncology Press release: Study Update

Dec 18, 2025, 8:30 AM EST - 7 months ago

Pyxis Oncology Slides: Study Update

2025-12-18T12:18:15.000Z - 7 months ago

Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin

MRK

2025-12-18T12:17:56.000Z - 7 months ago

Pyxis to present updated data from Phase 1 monotherapy study in mid-2026

2025-12-18T12:17:22.000Z - 7 months ago

Pyxis Oncology sees cash runway into 4Q26

Dec 18, 2025, 7:00 AM EST - 7 months ago

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2025-11-26T14:15:39.000Z - 8 months ago

Pyxis Oncology files $350M mixed securities shelf

Nov 26, 2025, 7:00 AM EST - 8 months ago

Pyxis Oncology Registration statement: Registration Filing

2025-11-24T12:35:39.000Z - 8 months ago

Pyxis Oncology price target raised to $8 from $5 at Stephens

Nov 11, 2025, 4:00 PM EST - 9 months ago

Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 2:30 PM EST - 9 months ago

Pyxis Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 4:00 PM EST - 9 months ago

Pyxis Oncology Quarterly report: Q3 2025

2025-11-03T12:12:11.000Z - 9 months ago

Pyxis Oncology reports Q3 EPS (35c), consensus (34c)

Nov 3, 2025, 7:00 AM EST - 9 months ago

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

2025-11-03T11:51:01.000Z - 9 months ago

Pyxis Oncology resumed with a Buy at Stifel

Oct 13, 2025, 4:05 PM EDT - 10 months ago

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

2025-10-09T11:35:39.000Z - 10 months ago

Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets

Oct 9, 2025, 7:30 AM EDT - 10 months ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Sep 30, 2025, 4:24 PM EDT - 10 months ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 10:30 AM EDT - 11 months ago

Pyxis Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-04T09:40:07.000Z - 11 months ago

Pyxis Oncology initiated with a Buy at Guggenheim

2025-09-03T20:31:05.000Z - 11 months ago

Pyxis Oncology initiated with a Buy at Guggenheim

Sep 3, 2025, 2:45 PM EDT - 11 months ago

Pyxis Oncology Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

2025-08-14T20:15:50.000Z - 1 year ago

Pyxis Oncology reports Q2 EPS (30c), consensus (35c)

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q2 2025

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 2:05 PM EDT - 1 year ago

Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 16, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Slides: Corporate Presentation

May 15, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 25, 2025, 1:17 PM EDT - 1 year ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 9, 2025, 11:30 AM EDT - 1 year ago

Pyxis Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q4 2024

Mar 18, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 2:20 PM EDT - 1 year ago

Pyxis Oncology Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 4, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Dec 19, 2024, 4:08 PM EST - 1 year ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Transcript: Status Update

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Slides: Status Update

Nov 20, 2024, 4:05 PM EST - 1 year ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 18, 2024, 7:00 AM EST - 1 year ago

Pyxis Oncology Quarterly report: Q3 2024

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Sep 13, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing

Sep 9, 2024, 2:00 PM EDT - 2 years ago

Pyxis Oncology Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 12:20 PM EDT - 2 years ago

Pyxis Oncology Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Slides: Q2 2024

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jun 10, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

May 30, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Earnings release: Q1 2024

May 14, 2024, 3:05 PM EDT - 2 years ago

Pyxis Oncology Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 16, 2024, 1:30 PM EDT - 2 years ago

Pyxis Oncology Transcript: Stifel Virtual Targeted Oncology Days Conference

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Registration statement: Registration Filing

Mar 27, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 21, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Earnings release: Q4 2023

Mar 13, 2024, 8:40 AM EDT - 2 years ago

Pyxis Oncology Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 7, 2024, 4:30 PM EST - 2 years ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Dec 19, 2023, 12:50 PM EST - 2 years ago

Pyxis Oncology Slides: Corporate Presentation

Nov 7, 2023, 4:30 PM EST - 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Earnings release: Q3 2023

Sep 27, 2023, 9:18 AM EDT - 3 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Aug 31, 2023, 4:01 PM EDT - 3 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 23, 2023, 8:35 AM EDT - 3 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Earnings release: Q2 2023

Aug 10, 2023, 2:56 PM EDT - 3 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 1, 2023, 4:01 PM EDT - 3 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Jul 10, 2023, 3:01 AM EDT - 3 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

May 30, 2023, 10:52 PM EDT - 3 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 8:30 AM EDT - 3 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Transcript: M&A Announcement

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Press release: M&A Announcement

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Slides: M&A Announcement

May 24, 2023, 6:45 AM EDT - 3 years ago

Pyxis Oncology to Acquire Apexigen

May 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

StockScanners Jul. 28 at 12:33 AM

$PYXS reached 2.99

0 · Reply

AC_TRADER Jul. 23 at 5:44 PM

$PYXS Chart made with @TrendSpider https://share.trendspider.com/chart/PYXS/7594xsw7hw

0 · Reply

dixiebull Jul. 23 at 1:06 PM

$ADVB $PYXS $NUVB $LABT $PN ADVB as usual the first one on my watchlist is the nicest

0 · Reply

dixiebull Jul. 23 at 11:18 AM

$ADVB $PYXS $NUVB $LABT $PN ADVB first on watchlist, as ususal

0 · Reply

AtariLynx Jul. 23 at 5:42 AM

$PYXS with no news it will back around 2.2 in the next days.

0 · Reply

InItToWinIt100 Jul. 23 at 5:37 AM

$PYXS Those $2.50 calls are looking good!

0 · Reply

hyenapete Jul. 23 at 5:13 AM

$PYXS

0 · Reply

StockScanners Jul. 23 at 2:31 AM

$PYXS keep watch if this holds above 2.45

0 · Reply

topstockalerts Jul. 22 at 10:21 PM

$PYXS there’s very little to dislike about this setup.

0 · Reply

dixiebull Jul. 22 at 8:52 PM

1 · Reply

Relee187200 Jul. 22 at 8:25 PM

$PYXS What happened? News?

2 · Reply

InItToWinIt100 Jul. 22 at 7:52 PM

$PYXS $2.70 next target https://www.trade-ideas.com/share.php?code=fB0A5JMzSqqGRqK9MTSJQjMq7pBGVSGG

0 · Reply

InItToWinIt100 Jul. 22 at 7:02 PM

$PYXS August $2.50 calls

0 · Reply

Biotech_Beast Jul. 15 at 1:05 AM

Key head and neck readouts from, $PYXS's Micvo and $GMAB's petosemtamab ahead in H2'26. An update from $BCAX is out of the way for now I think. I took a look at PYXS in more detail. BVF LP is onboard as an investor with the recent raise. https://seekingalpha.com/article/4921917-pyxis-oncology-the-market-might-have-already-ruled-on-micvotabart-pelidotin

0 · Reply

Zackpedia Jul. 14 at 8:45 PM

$PYXS Down to 2.3, you could’ve sold when I alerted.

1 · Reply

AtariLynx Jul. 14 at 2:39 PM

$PYXS Nice price to add!

0 · Reply

RadioIsotope25 Jul. 13 at 1:18 PM

Radiopharm Theranostics ($RADX) Jumps as Nuclear-Medicine Interest Builds $LNTH $IMNM $PYXS Source: Kalkine https://kalkine.com.au/news/healthcare/radiopharm-theranostics-asxrad-jumps-as-nuclear-medicine-interest-builds

0 · Reply

Zackpedia Jul. 13 at 9:41 AM

$PYXS Down to 2.6 now! You could’ve…

0 · Reply

AtariLynx Jul. 10 at 3:12 PM

$PYXS also look at LTRN. Fair price above 4$

0 · Reply

AtariLynx Jul. 10 at 3:02 PM

$PYXS Nice price to add

0 · Reply

Zackpedia Jul. 9 at 2:22 PM

$PYXS Down to 2.6, you could’ve sold when I alerted and bought back now if you wanted.

0 · Reply

Zardiw Jul. 7 at 11:11 PM

DDAmanda Scanner win: $CLRO +98%. Also found early: $BATL $EDHL $PYXS Next one will be here: https://DDAmanda.com

1 · Reply

Market Cap	165.36M
Revenue (ttm)	13.86M
Net Income (ttm)	-79.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-574.46%
Debt to Equity Ratio	0.00

Volume	987,300
Avg Vol	994,830
Day's Range	N/A - N/A
Shares Out	63.36M
Stochastic %K	91%
Beta	1.30
Analysts	Strong Sell
Price Target	$6.75